TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00404742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.4 mg/kg, twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.6 mg/kg, twice a day (BID)
Study: NCT04219215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 100% O2 in oxygen chamber
Description: Application of 100% O2 in an hyperbaric oxygen chamber

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 100% O2 in oxygen chamber
Description: Application of 100% O2 in an hyperbaric oxygen chamber

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 21% O2 in oxygen chamber
Description: Application of ambient air (21% O2) in an hyperbaric oxygen chamber

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 21% O2 in oxygen chamber
Description: Application of ambient air (21% O2) in an hyperbaric oxygen chamber
Study: NCT01013584

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: daily dose
Study: NCT03024034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
Study: NCT00843934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
Study: NCT03060317

Intervention type: BEHAVIORAL
Intervention: Examination with neurological scales.
Description: Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
Study: NCT01259557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 2 times, Intra-muscular injection, Maximum dosage total 60U
Study: NCT02540525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ophira
Description: The procedure will be perfomed with a single incision in anterior wall vagina

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator sling
Description: Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
Study: NCT04437641

Intervention type: OTHER
Intervention: Tobacco questionnaire
Description: A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact.
Study: NCT01974102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully for Health (PMH)
Description: Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
Study: NCT02240524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Study: NCT02143375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 810 Diode Laser
Description: The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
Study: NCT02240524

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Systemic chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Study: NCT01832844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group  with scan prior to infiltration 
Description: Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group  without scan
Study: NCT01128855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg GSK2402968
Description: Weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg/kg GSK2402968
Description: Weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9 mg/kg GSK2402968
Description: Weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg/kg GSK2402968
Description: Weekly subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly Placebo
Study: NCT04379635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered via Intravenous (IV) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin injection
Description: administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: administered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel injection
Description: administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: administered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed Disodium
Description: administered via IV infusion
Study: NCT03611075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study
Study: NCT04185961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVERA-RAPHA with 60mmHG
Description: Apply EVERA-RAPHA with 60mmHG for 4weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVERA-RAPHA with 100mmHG
Description: Apply EVERA-RAPHA with 100mmHG for 4weeks
Study: NCT01232959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal Cholecystectomy
Description: A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
Study: NCT01839318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Study: NCT01128855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly Placebo
Study: NCT04317794

Intervention type: DRUG
Intervention: Nusinersen Sodium Injection
Description: Administered as specified in the treatment arm.
Study: NCT01333800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beclomethasone
Description: 200 to 400 mcg per day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 80 to 160 mcg per day for 6 months
Study: NCT03137836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM .
Study: NCT01237496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly
Study: NCT05063045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smart-cloth assisted home nursing care
Description: Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
Study: NCT03643055

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-fluorocholine PET/CT
Description: 18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
Study: NCT01079949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hLH + r-hFSH
Description: Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hFSH
Description: Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
Study: NCT00780910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: 750 mg every 8 hours for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks
Study: NCT04105127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - Anterior resin builds-ups
Description: After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - Posterior resin builds-ups
Description: After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
Study: NCT00368979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT00089024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
Study: NCT04379635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: administered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo to match tislelizumab IV infusion
Study: NCT01859884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inform Me: web-based education tool
Description: The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
Study: NCT04379869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: Single dose of NNZ-2591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: Single dose of NNZ-2591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: Single dose of NNZ-2591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: Single dose of NNZ-2591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Comparator for double-blind MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Comparator for double-blind MAD
Study: NCT02448524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent
Description: Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
Study: NCT02733887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: 18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
Study: NCT02448524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIVOLI
Description: Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
Study: NCT02733887

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
Study: NCT06251674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long-axis needle release
Description: The participants received one session of ultrasound-guided long-axis TCL needle release.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: short-axis needle release
Description: The participants received one session of ultrasound-guided long-axis TCL needle release.
Study: NCT00476463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
Study: NCT03484949

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-endoscopic screening risk assessment
Description: pre-endoscopic screening risk assessment
Study: NCT02355041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Replacement-based Weight Loss Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video
Description: Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.